Researchers are increasingly interested in drugs that block a brain receptor called mGluR5 (like methyl-phenyl-ethynyl-pyridine (MPEP) and methyl-thiazolyl ethynyl pyridine (MTEP), which have real potential to treat both epilepsy and depression simultaneously [226,227]. This evidence concerns the gene GRM5 and depressive symptom measurement.